Experts Stress Need For Final Trial Vaccine Data

"); jQuery("#212 h3").html("

Related News Programmes

"); });

2021-01-30 HKT 13:56

Share this story

facebook

  • Experts stress need for final trial vaccine data

SAR government vaccine advisors on Saturday said they would only approve Covid vaccines for emergency use after phase three clinical trial results had been provided.

The government has placed one of its vaccine orders with mainland firm Sinovac, but plans for the first batch of this vaccine to arrive in February have been derailed after the company delayed the release of its final stage test data.

Earlier this week, the Chief Executive Carrie Lam said she had asked Beijing to provide the SAR with vaccines developed or manufactured on the mainland. Media reports said this could include vaccines manufactured by another mainland drug company, Sinopharm, with final stage data also pending.

Both firms have handed in trial data to the World Health Organization, which is now reviewing the vaccines for emergency use, although they have already been used in vaccination programmes on the mainland.

Infectious diseases specialist Professor Ivan Hung said he believed both companies would soon provide the necessary data. Hung, who is on the government advisory panel for Covid-19 vaccines, said Hong Kong's strong health service meant it could wait a little longer.

"We have to wait for the phase three results. I think the phase three results will be very, very important for the advisory panel to assess the safety, as well as the efficacy of the vaccine. There is no rush for us to jump in. We have time, and our health system remains very robust, so I think we could afford to wait for the phase three results for assessment," he said.

Another member on the advisory panel - former Controller for the Centre for Health Protection, Thomas Tsang - said vaccines would be vetted in the same manner, regardless of where they were produced.

Hong Kong has already ordered and approved a vaccine by Germany's BioNTech. Authorities have also ordered the Oxford University vaccine by Anglo-Swedish firm AstraZeneca, which the CE said is expected to arrive in Hong Kong in the second half the year.

Meanwhile, the Secretary for the Civil Service Patrick Nip, who is in charge of the government inoculation initiative, has said the vaccination programme can start once the BioNTech vaccine arrives some time in late February.

Nip said vaccination centres would be set up across the city and that they would operate daily for at least six months, between 8 am and 8 pm.

RECENT NEWS

How Core Modernisation Is Paving The Way For Invisible Banking

In an era dominated by digital innovation, the banking sector is evolving rapidly to meet the modern consumer’s deman... Read more

ZA Bank Financial Performance Shows Strong Growth, Reduced Losses Last Year

ZA Bank, a virtual bank in Hong Kong, has reported a substantial increase in its financial performance for the past yea... Read more

Elon Musk Impersonated In Suspected Quantum AI Crypto Fraud

The Securities and Futures Commission (SFC) has issued a public warning about suspected fraud involving the entity know... Read more

Why Hong Kong Is Primed For A Crypto ETF Breakthrough

In the dynamic landscape of global finance, Hong Kong has emerged as a frontrunner in innovative exchange-traded funds ... Read more

MixCare Health And Pacific Prime Collaborate On Digital Health Platform

MixCare Health, a Hong Kong-based digital health and wellness platform, has partnered with Pacific Prime, an internatio... Read more

Mox Bank Revenue Triples In 2023 Driven By New Services And Customer Growth

Mox Bank announced that it has tripled its revenue in 2023, driven by an increase in its customer base, deposits, and l... Read more